Drug
MK-7240 (PRA023)
Status:
Phase 2
Condition:
Systemic Sclerosis ILD
Intervention Type:
Subcutaneous (SC) Injection
Funder Type:
Industry
Drug Details
MK-7240 is an investigational humanized monoclonal antibody directed to tumor necrosis factor (TNF)-like ligand 1A (TL1A).
Study Purpose
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.